Insulin signaling pathways in a patient with insulin resistance of difficult management – a case report.
Insulin signaling pathways in a patient with insulin resistance of difficult management - a case report.
Diabetol Metab Syndr. 2009 Nov 26;1(1):23
Authors: Taboada GF, de Freitas MS, Correa FH, Andrade CM, Gomes MB
ABSTRACT: Insulin signaling pathways were investigated in a 33 year-old woman with immunologic insulin resistance. Her past medical history was remarkable for intermittent use of insulin and allergic reactions to several drugs and determination of plasmatic anti-insulin antibodies corroborated the clinical suspicion of immune mediated insulin resistance (8074 nU/ml - RIA - Ref value: <60). Treatment with several immunossupressive regimens was tried but the results were disappointing. Possible subcellular mechanisms of insulin resistance were investigated by performing a skeletal muscle biopsy. The expression of insulin receptor (IR), IRS-1 and GLUT-4 was evaluated in total extract from muscle tissue by Western blotting. IR, IRS-1 and GLUT-4 immunocontent did not present marked alterations. However, when IRS-1 protein content associated to membrane and IR tyrosine phosphorylation were analyzed, no IR activity was observed, despite the expressive subcellular localization. Also, tissue presented low levels of membrane-associated GLUT-4. When in vitro stimulation was undertaken, tissue was showed to be responsive to insulin. Our results evidenced that even though IR expression was normally occuring, IR tyrosine kinase activity of muscle receptor beta-subunit was down-regulated consequently decreasing GLUT-4 translocation, despite its normal expression in muscle. These findings were compatible with decreased insulin binding to IR, probably because of sequestration by anti-insulin antibodies. In conclusion, this patient has immunologic insulin resistance and treatment should be based on immunosuppressive drugs as tolerated.
PMID: 19941665 [PubMed - as supplied by publisher]
Sponsored Content:
This entry was posted on Saturday, November 28th, 2009 at 6:21 am and is filed under Diabetol Metab Syndr. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.
